Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $514.70 million. The enterprise value is $316.84 million.
| Market Cap | 514.70M |
| Enterprise Value | 316.84M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 70.90 million shares outstanding. The number of shares has increased by 13.47% in one year.
| Shares Outstanding | 70.90M |
| Shares Change (YoY) | +13.47% |
| Shares Change (QoQ) | +9.07% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 62.44% |
| Float | 70.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,208.22 |
| Forward PS | n/a |
| PB Ratio | 2.65 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 743.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.26, with zero debt.
| Current Ratio | 17.26 |
| Quick Ratio | 16.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,526.06 |
Financial Efficiency
Return on equity (ROE) is -52.00% and return on invested capital (ROIC) is -49.42%.
| Return on Equity (ROE) | -52.00% |
| Return on Assets (ROA) | -47.30% |
| Return on Capital (ROIC) | -49.42% |
| Revenue Per Employee | $7,220 |
| Profits Per Employee | -$1.50M |
| Employee Count | 59 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.08% in the last 52 weeks. The beta is 0.06, so Altimmune's price volatility has been lower than the market average.
| Beta (1Y) | 0.06 |
| 52-Week Price Change | +39.08% |
| 50-Day Moving Average | 9.26 |
| 200-Day Moving Average | 6.01 |
| Relative Strength Index (RSI) | 39.49 |
| Average Volume (30 Days) | 4,681,193 |
Short Selling Information
The latest short interest is 20.37 million, so 28.73% of the outstanding shares have been sold short.
| Short Interest | 20.37M |
| Short Previous Month | 17.73M |
| Short % of Shares Out | 28.73% |
| Short % of Float | 28.96% |
| Short Ratio (days to cover) | 4.79 |
Income Statement
In the last 12 months, Altimmune had revenue of $426,000 and -$88.45 million in losses. Loss per share was -$1.66.
| Revenue | 426,000 |
| Gross Profit | 426,000 |
| Operating Income | -95.93M |
| Pretax Income | -88.45M |
| Net Income | -88.45M |
| EBITDA | -87.94M |
| EBIT | -88.41M |
| Loss Per Share | -$1.66 |
Balance Sheet
The company has $197.86 million in cash and no debt, giving a net cash position of $197.86 million or $2.79 per share.
| Cash & Cash Equivalents | 197.86M |
| Total Debt | n/a |
| Net Cash | 197.86M |
| Net Cash Per Share | $2.79 |
| Equity / Book Value | 194.10M |
| Book Value Per Share | 2.74 |
| Working Capital | 197.48M |
Cash Flow
In the last 12 months, operating cash flow was -$75.81 million and capital expenditures -$47,000, giving a free cash flow of -$75.86 million.
| Operating Cash Flow | -75.81M |
| Capital Expenditures | -47,000 |
| Free Cash Flow | -75.86M |
| FCF Per Share | -$1.43 |
Margins
Gross margin is 100.00%, with operating and profit margins of -22,518.54% and -20,762.21%.
| Gross Margin | 100.00% |
| Operating Margin | -22,518.54% |
| Pretax Margin | -20,762.21% |
| Profit Margin | -20,762.21% |
| EBITDA Margin | -20,642.02% |
| EBIT Margin | -20,753.99% |
| FCF Margin | -17,806.81% |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -13.47% |
| Shareholder Yield | -13.47% |
| Earnings Yield | -17.18% |
| FCF Yield | -14.74% |
Analyst Forecast
The average price target for Altimmune is $15.00, which is 106.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 106.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 309.12% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 15.31 and a Piotroski F-Score of 2.
| Altman Z-Score | 15.31 |
| Piotroski F-Score | 2 |